Genetically modified benzylisoquinoline alkaloid-producing host cells with modified efflux transporter gene expression
AssigneeRiver Stone Biotech Aps
InventorsEsben Halkjaer HANSEN, Laura Tatjer RECORDA, Pernille Lund LYNEBORG, Giedre BACINSKAJA, Jens HOUGHTON-LARSEN
Life of this patent
Estimating the term…
Abstract
The invention relates to genetically modified hosts cell comprising a recombinant pathway having enhanced production of one or more benzylisoquinoline alkaloids or glycosylated benzylisoquinoline alkaloid, wherein the host cell has been further modified so as to have an increased ability to export end products of the recombinant pathway (such as nororipavine or gly-nororipavine).
Claims36
A recombinant microbial host cell capable of producing one or more BIA, BIA-glycoside, oripavine or glycosylated oripavine or glucosylated oripavine, thebaine, northebaine, nororipavine, glycosylated nororipavine or glucosylated nororipavine, wherein the host cell comprises a recombinant polynucleotide comprising a promoter operably linked to an ABC transporter effluxing one or more BIA or BIA-glycoside products.
The recombinant microbial host cell of any preceding claim, wherein the transcription factor is PDR 1, PDR3, PDR8 and/or YRR1.
A recombinant microbial host cell according to any preceding claim, wherein the recombinant microbial host cell excretes the BIA, BIA-glycoside, oripavine, glycosylated oripavine or glucosylated oripavine, thebaine, northebaine, nororipavine, glycosylated nororipavine or glucosylated nororipavine produced by the recombinant microbial host cell, at greater than 2%, preferably greater than 5%, preferably greater than 10%, preferably greater than 20% more excretion compared to a negative control recombinant microbial host cell not expressing the ABC transporter during cell exponential phase and BIA production.
A recombinant microbial host cell according to any preceding claim, wherein the recombinant microbial host cell produces the one or more of the BIAs at greater than 2%, preferably more than 5%, preferably more than 10%, preferably more than 20%, preferably more than 50% more than a negative control recombinant microbial host cell not expressing the ABC transporter during cell exponential phase and BIA production.
A recombinant microbial host cell according to any preceding claim, wherein the one or more excreted BIAs are thebaine, nororipavine, oripavine, glucosylated oripavine or glucosylated nororipavine.
The recombinant microbial host cell of any preceeding claim, wherein the ABC transporter is an ABC transporter involved in drug efflux or xenobiotic efflux.
The recombinant microbial host cell of any preceeding claim, wherein the ABC transporter comprises a Walker A sequence G(A/S/R)(S/T)GAGK(S/T), a linker sequence (L/V)SGG(E/Q), and a Walker B sequence comprising four hydrophobic residues, an optional additional fifth hydrophobic residue and a D such that (I/L)(I/L)(I/V/L)(F/L/M)XD where X represents the optional additional hydrophobic residue or no additional residue.
The recombinant microbial host cell of any preceding claim, wherein the ABC transporter is:
- a. an ABCC/multi-drug resistance associated protein (MRP) ABC transporters, or
- b. an ABCG/pleiotropic drug resistance (PDR) ABC transporters.
The recombinant microbial host cell of any preceding claim, wherein the ABC transporter is not native to a BIA-producing plant.
The recombinant microbial host cell of any preceding claim, wherein the ABCC/multi-drug resistance associated protein (MRP) ABC transporter is:
- a. a polypeptide comprising a sequence having at least 45%, such as at least 60%, such as at least 70%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to SEQ ID No. 872, 910, 912, 914, 918, 920, 922, 924, 926, 928, 930, 932, 934, 936, 938, 940, 942, 956, 960, 962, 964, 966, 970, 1032, 1034, 1038 or 1040 or
- b. encoded by a nucleic acid sequence having at least 45%, such as at least 60%, such as at least 70%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to SEQ ID No. 871, 909, 911, 913, 917, 919, 921, 923, 925, 927, 929, 931, 933, 935, 937, 939, 941, 955, 959, 961, 963, 965, 969, 1031, 1033, 1037 or 1039 or genomic DNA thereof.
The recombinant microbial host cell of any preceding claim, further comprising:
- a) one or more heterologous CYP demethylases capable of converting thebaine into northebaine, thebaine into oripavine, northebaine into nororipavine and/or oripavine into nororipavine, and one or more demethylase cytochrome P450 reductase (demethylase-CPR), and/or
- b) heterologous sequences encoding:
- i. a tyrosine hydroxylase (TH) converting L-tyrosine into L-dopa, and
- ii. optionally, a TH-CPR capable of reducing the TH of i), and
- iii. a L-dopa decarboxylase (DODC) converting L-dopa into dopamine, or a tyrosine decarboxylase (TYDC) converting L-dopa into dopamine, and
- iv. a monoamine oxidase converting dopamine into 3,4-DHPAA, or a N-methyl-coclaurine hydroxylase (NMCH) converting (S)-Coclaurine into (S)-3′-hydroxycoclaurine and/or (S)—N-Methylcoclaurine into (S)-3′-Hydroxy-N-Methylcoclaurine;
- and
- v. a norcoclaurine synthase (NCS) converting Dopamine and 4-HPAA into (S)-norcoclaurine and/or 3,4-DHPAA and dopamine to NLDS, and
- vi. a 6-O-methyltransferase (6-OMT) converting (S)-norcoclaurine into (S)-Coclaurine and/or norlaudanosoline into (S)-3′-Hydroxy-coclaurine, and
- vii. a coclaurine-N-methyltransferase (CNMT) converting (S)-Coclaurine into (S)—N-Methylcoclaurine and/or (S)-3′-hydroxycoclaurine into (S)-3′-hydroxy-N-methyl-coclaurine, and
- viii. a 3′-hydroxy-N-methyl-(S)-coclaurine 4′-O-methyltransferase (4′-OMT) converting (S)-3′-Hydroxy-N-Methylcoclaurine into (S)-reticuline, and
- ix. a 1,2-dehydroreticuline synthase-1,2-dehydroreticuline reductase (DRS-DRR) converting (S)-reticuline into (R)-reticuline comprised of one or more proteins, and
- x. a salutaridine synthase (SAS) converting (R)-reticuline into Salutaridine, and
- xi. a salutaridine reductase (SAR) converting Salutaridine to Salutaridinol, and
- xii. a salutaridinol 7-O-acetyltransferase (SAT) converting Salutaridinol into 7-O-acetylsalutaridinol, and
- xiii. a thebaine synthase (THS) converting 7-O-acetylsalutaridinol or 7-O-acetylsalutaridinol acetate into thebaine;
- c) and optionally, one or more glycosyl transferases capable of transferring a glycosyl moiety to a BIA, oripavine or nororipavine.
The recombinant microbial host cell of any preceding claim, wherein the one or more glycosyltransferases (UGT) is an aglycone O-UGT or an aglycone O-glucosyltransferase.
The recombinant microbial host cell of any preceding claim, wherein the one or more glycosyltransferases (UGT):
- a. comprises an amino acid sequence having at least 60%, such as at least 70%, such at least 75%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to a UGT comprised in any one of SEQ ID NO:
- 880, 882, 878, 884, 886, 888, 890, 892, 894, 896, or 898;
- or
- b. is encoded by a nucleic acid sequence having at least 60%, such as at least 70%, such at least 75%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to SEQ ID No. 879, 881, 877, 883, 885, 887, 889, 891, 893, 895 or 897, or genomic DNA thereof.
The recombinant microbial host cell of any preceding claim, wherein the recombinant microbial host cell is a yeast.
The recombinant microbial host cell of any preceding claim, wherein the recombinant microbial host cell is Saccharomyces cerevisiae.
The recombinant microbial host cell of any preceding claim, further comprising an uptake transporter capable of transporting an opioid, such as oripavine, into the recombinant host cell.
The recombinant microbial host cell of any preceding claim, further comprising an operative biosynthetic pathway capable of producing the thebaine, northebaine, oripavine and/or nororipavine, wherein the pathway comprises one or more polypeptides selected from:
- a) a 3-deoxy-D-arabino-2-heptulosonic acid 7-phosphate synthase (DAHP synthase) converting PEP and E4P into DAHP;
- b) a 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase (aro1) converting 3-phosphoshikimate and PEP into EPSP;
- c) an aro1 polypeptide converting DHAP and PEP into EPSP;
- d) a chorismate synthase converting EPSP into Chorismate;
- e) a chorismate mutase converting Chorismate into prephenate;
- f) a prephenate dehydrogenase (Tyr1) converting prephenate into 4-HPP;
- g) an aromatic aminotransferase converting 4-HPP into L-Tyrosine;
- h) a tyrosine hydroxylase (TH) converting L-tyrosine into L-dopa
- i) a TH-CPR capable of reducing the TH of h);
- j) a L-dopa decarboxylase (DODC) converting L-dopa into dopamine;
- k) a Tyrosine decarboxylase (TYDC) converting L-dopa into dopamine;
- l) a hydroxyphenylpyruvate decarboxylase (HPPDC) converting 4-HPP into 4-HPPA;
- m) a monoamine oxidase converting dopamine into 3,4-DHPAA;
- n) a norcoclaurine synthase (NCS) converting Dopamine and 4-HPAA into (S)-norcoclaurine;
- o) a 6-O-methyltransferase (6-OMT) converting (S)-norcoclaurine into (S)-Coclaurine and/or norlaudanosoline into (S)-3′-Hydroxy-coclaurine;
- p) a coclaurine-N-methyltransferase (CNMT) converting (S)-Coclaurine into (S)—N-Methylcoclaurine and/or (S)-3′-hydroxycoclaurine into (S)-3′-hydroxy-N-methyl-coclaurine;
- q) a N-methyl-coclaurine hydroxylase (NMCH) converting (S)-Coclaurine into (S)-3′-hydroxycoclaurine and/or (S)—N-Methylcoclaurine into (S)-3′-Hydroxy-N-Methylcoclaurine;
- r) a 3′-hydroxy-N-methyl-(S)-coclaurine 4′-O-methyltransferase (4′-OMT) converting (S)-3′-Hydroxy-N-Methylcoclaurine into (S)-reticuline;
- s) a 1,2-dehydroreticuline synthase-1,2-dehydroreticuline reductase (DRS-DRR) converting (S)-Reticuline into (R)-reticuline;
- t) a salutaridine synthase (SAS) converting (R)-reticuline into Salutaridine;
- u) a salutaridine reductase (SAR) converting Salutaridine to Salutaridinol;
- v) a salutaridinol 7-O-acetyltransferase (SAT) converting Salutaridinol into 7-O-acetylsalutaridinol;
- w) a thebaine synthase (THS) converting 7-O-acetylsalutaridinol or 7-O-acetylsalutaridinol acetate into thebaine;
- x) a demethylase converting thebaine into oripavine, thebaine into northebaine, oripavine into nororipavine and/or northebaine into nororipavine;
- and/or
- y) a demethylase-CPR capable of reducing the demethylase of x).
A cell culture comprising the recombinant microbial host cell of any preceding claim plus cell growth medium.
Dependencies are inferred from the claim text.